Sign in Sign up for free

Last updated: 13 April 2020 at 12:14pm EST

Peter Buzy Net Worth




The estimated Net Worth of Peter L Buzy is at least $6.84 Million dollars as of 29 May 2019. Mr. Buzy owns over 44,500 units of Catalent stock worth over $2,653,535 and over the last 5 years he sold CTLT stock worth over $0. In addition, he makes $4,186,050 as Chairman - Gene Therapy at Catalent.

Mr. Buzy CTLT stock SEC Form 4 insiders trading

Peter has made over 1 trades of the Catalent stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 44,500 units of CTLT stock worth $2,008,285 on 29 May 2019.

The largest trade he's ever made was buying 44,500 units of Catalent stock on 29 May 2019 worth over $2,008,285. On average, Peter trades about 11,125 units every 0 days since 2019. As of 29 May 2019 he still owns at least 44,500 units of Catalent stock.

You can see the complete history of Mr. Buzy stock trades at the bottom of the page.





Peter Buzy biography

Peter Buzy has been appointed as Chairman - Gene Therapy of the Company effective 6/1/2020. Mr. Buzy was named President, Gene Therapy in May 2019, when we acquired Paragon. Prior to joining Catalent via the acquisition, Mr. Buzy had served as President & Chief Executive Officer of Paragon since 2016, having joined Paragon in 2014 as its Chief Operating Officer. With over 25 years of successful executive management experience, he grew Paragon into a premier contract development and manufacturing organization with a leading position in gene therapy and next-generation vaccines. Prior to that, Mr. Buzy spent over 13 years as a senior executive at Martek Biosciences Corporation, a leader in the innovation, development, production, and sale of high-value products from microbial sources that was publicly traded until being acquired. He played a key role in transforming Martek’s business from an R&D company to a fully integrated and profitable commercial organization with over $470 million in annual sales. Prior to his tenure at Martek, Mr. Buzy spent 13 years at Ernst & Young, where he advanced to Partner in the Northern Virginia High Technology and Life Science Practice, serving a variety of private and publicly traded biotechnology companies. Mr. Buzy earned his BBA in accounting from Salisbury University in Maryland and serves on the Board and Executive Committees of the Technology Council of Maryland.

What is the salary of Peter Buzy?

As the Chairman - Gene Therapy of Catalent, the total compensation of Peter Buzy at Catalent is $4,186,050. There are 1 executives at Catalent getting paid more, with John Chiminski having the highest compensation of $8,514,990.



How old is Peter Buzy?

Peter Buzy is 59, he's been the Chairman - Gene Therapy of Catalent since 2020. There are 8 older and 19 younger executives at Catalent. The oldest executive at Catalent Inc. is Rolf Classon, 75, who is the Independent Director.

What's Peter Buzy's mailing address?

Peter's mailing address filed with the SEC is C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET, NJ, 08873.

Insiders trading at Catalent

Over the last 10 years, insiders at Catalent have traded over $2,686,980,380 worth of Catalent stock and bought 123,000 units worth $5,376,345 . The most active insiders traders include Management Associates V L.L..., Peter Zippelius, and Frank A Damelio. On average, Catalent executives and independent directors trade stock every 17 days with the average trade being worth of $22,866,018. The most recent stock trade was executed by Ricky Hopson on 2 August 2024, trading 662 units of CTLT stock currently worth $39,429.



What does Catalent do?

catalyst + talent. our name combines these ideas. from drug and biologic development services to delivery technologies to supply solutions, we are the catalyst for your success. with over 80 years of experience, we have the deepest expertise, the broadest offerings, and the most innovative technologies to help you get more molecules to market faster, enhance product performance and provide superior, reliable manufacturing and packaging results. catalent develops. with our broad range of expert services we drive faster, more efficient development timelines to help you take more molecules to market and create more effective products. catalent delivers. as the world leader in drug delivery innovations, we have a proven record of enhancing bioavailability, solubility and permeability, improving ease and route of administration, and increasing patient compliance for better treatments. catalent supplies. globally positioned to serve all your manufacturing and commercial packaging needs, we p



What does Catalent's logo look like?

Catalent Inc. logo

Complete history of Mr. Buzy stock trades at Catalent

Date
#
Company
 Insider
Trans.
Transaction
 Shares Price per share Total value Shares after Source
29 May 2019 CTLT Catalent Inc. Peter L Buzy
President and Gene Therapy
 Buy 44,500 $45.13 $2,008,285
29 May 2019
44,500 ↗


Catalent executives and stock owners

Catalent executives and other stock owners filed with the SEC include: